Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting

Pharmacogenetics and Genomics

Volumn 23, Issue 10, 2013, Pages 535-548

  Hall Flavin, Daniel K ^a   Winner, Joel G ^c,d   Allen, Josiah D ^d   Carhart, Joseph M ^d   Proctor, Brian ^b   Snyder, Karen A ^a   Drews, Maureen S ^a   Eisterhold, Linda L ^a   Geske, Jennifer ^a   Mrazek, David A ^a  

^a MAYO CLINIC   (United States)

^b Franciscan Skemp Mayo Health System   (United States)

^c Winner Psychiatry   (United States)

^d AssureRx Health   (United States)

Author keywords

antidepressant; genomics; pharmacogenomic; translational medicine; treatment resistant depression

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ARIPIPRAZOLE; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; DESIPRAMINE; DESVENLAFAXINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; IMIPRAMINE; MIRTAZAPINE; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; QUETIAPINE; RISPERIDONE; SELEGILINE; SEROTONIN 2A RECEPTOR; SEROTONIN TRANSPORTER; SERTRALINE; TRAZODONE; UNINDEXED DRUG; VENLAFAXINE; ZIPRASIDONE;

ADULT; AGED; ARTICLE; FEMALE; GENE MUTATION; GENOTYPE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OUTPATIENT; PATIENT HEALTH QUESTIONNAIRE; PHARMACOGENOMICS; PHYSICIAN; PRIORITY JOURNAL; QUICK INVENTORY OF DEPRESSIVE SYMPTOMATOLOGY CLINICIAN RATED; REMISSION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; ARYL HYDROCARBON HYDROXYLASES; CITALOPRAM; COHORT STUDIES; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; DEPRESSIVE DISORDER, MAJOR; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; OUTPATIENTS; PHARMACOGENETICS; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84885082776     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3283649b9a     Document Type: Article

References (35)

1. Kemp AH, Gordon E, Rush AJ, Williams LM. Improving the prediction of treatment response in depression: Integration of clinical, cognitive, psychophysiological, neuroimaging, and genetic measures. CNS Spectr 2008; 13:1066-1086, quiz 1087-1088.
2. Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006; 354:1231-1242.
3. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR. D report. Am J Psychiatry 2006; 163:1905-1917.
4. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353:1209-1223.
5. Thase ME. STEP-BD and bipolar depression: What have we learned? Curr Psychiatry Rep 2007; 9:497-503.
6. Simon GE, Perlis RH. Personalized medicine for depression: Can we match patients with treatments? Am J Psychiatry 2010; 167:1445-1455.
7. Perlis RH. Pharmacogenetic studies of antidepressant response: how far from the clinic? Psychiatr Clin North Am 2007; 30:125-138.
8. Mrazek DA. Psychiatric Pharmacogenomics. New York, NY: Oxford University Press; 2010.
9. Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I, Brockmoller J. Pharmacogenetics of antidepressants and antipsychotics: The contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004; 9:442-473.
10. Mrazek DA, Biernacka JM, O'Kane DJ, Black JL, Cunningham JM, Drews MS, et al. CYP2C19 variation and citalopram response. Pharmacogenet Genomics 2011; 21:1-9.
11. Licinio J, Wong ML. Pharmacogenomics of antidepressant treatment effects. Dialogues Clin Neurosci 2011; 13:63-71.
12. Rundell JR, Shinozaki G. Pharmacogenomic considerations in patients with both comorbid medical and psychiatric illness. Prim Psychiatry 2010; 17:33-38.
13. Hall-Flavin DK, Schneekloth TD, Allen JA. Translational psychiatry: Bringing pharmacogenomic testing into clinical practice. Prim Psychiatry 2010; 17:39-44.
14. Kung S, Li X. The clinical use of pharmacogenomic testing in treatmentresistant depression. Prim Psychiatry 2010; 17:46-51.
15. Wall CA, Oldenkamp C, Swintak C. Safety and efficacy pharmacogenomics in pediatric psychopharmacology. Prim Psychiatry 2010; 17:53-58.
16. Rundell JR, Staab JP, Shinozaki G, Saad-Pendergrass D, Moore K, McAlpine D, Mrazek D. Pharmacogenomic testing in a tertiary care outpatient psychosomatic medicine practice. Psychosomatics 2011; 52:141-146.
17. Rundell JR, Staab JP, Shinozaki G, McAlpine D. Serotonin transporter gene promotor polymorphism (5-HTTLPR) associations with number of psychotropic medication trials in a tertiary care outpatient psychiatric consultation practice. Psychosomatics 2011; 52:147-153.
18. Mrazek DA, Lerman C. Facilitating clinical implementation of pharmacogenomics. JAMA 2011; 306:304-305.
19. Collins FS. Reengineering translational science: The time is right. Sci Transl Med 2011; 3:90cm17.
20. Gaughran F, Kapur S. How change comes: Translating biological research into care. The Psychiatrist 2011; 35:321-324.
21. Hall-Flavin DK, Winner JG, Allen JD, Jordan JJ, Nesheim RS, Snyder KA, et al. Using a pharmacogenomic algorithm to guide the treatment of depression. Transl Psychiatry 2012; 2:e172. doi:10.1038/tp.2012.99.
22. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56-62.
23. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6:278-296.
24. Rush AJ. Sequenced treatment alternatives to relieve depression (STAR.*D) protocol. Control Clin Trials 2001; 25:119-142.
25. Trivedi MH, Rush AJ, Ibrahim HM, Carmody TJ, Biggs MM, Suppes T, et al. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: A psychometric evaluation. Psychol Med 2004; 34:73-82.
26. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: Validity of a brief depression severity measure. J Gen Intern Med 2001; 16:606-613.
27. Rush AJ, Bernstein IH, Trivedi MH, Carmody TJ, Wisniewski S, Mundt JC, et al. An evaluation of the quick inventory of depressive symptomatology and the Hamilton rating scale for depression: A sequenced treatment alternatives to relieve depression trial report. Biol Psychiatry 2006; 59:493-501.
28. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): A psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003; 54:573-583.
29. Juü rgens G, Jacobsen CB, Rasmussen HB, Werge T, Nordentoft M, Andersen SE. Utility and adoption of CYP2D6 and CYP2C19 genotyping and its translation into psychiatric clinical practice. Acta Psychiatr Scand 2012; 125:228-237.
30. FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. 28 March 2012. Available at: http://www.fda.gov/ Drugs/DrugSafety/ucm297391.htm [Accessed 11 December 2012].
31. Perahia DG, Wang F, Mallinckrodt CH, Walker DJ, Detke MJ. Duloxetine in the treatment of major depressive disorder: A placebo- and paroxetinecontrolled trial. Eur Psychiatry 2006; 21:367-378.
32. Rossi A, Barraco A, Donda P. Fluoxetine: A review on evidence based medicine. Ann Gen Hosp Psychiatry 2004; 3:1-8.
33. Apler A. Citalopram for major depressive disorder in adults: A systematic review and meta-analysis of published placebo-controlled trials. BMJ Open 2011; 1:e000106.
34. Stark P, Harrison CD. A review of multicenter controlled studies of fluoxetine vs. imipramine and placebo in outpatients with major depressive disorder. J Clin Psychiatry 1985; 46:53-58.
35. National Institute for Clinical Excellence. Depression: Management of depression in primary and secondary care. Clinical practice guideline No. 23. London: NICE; 2004.